Atomoxetine is NOT Recommended as a Treatment for Primary Anxiety Disorders
Atomoxetine should not be used to treat anxiety as a primary condition. While it is FDA-approved for ADHD and has been shown not to worsen anxiety in patients with comorbid ADHD and anxiety disorders, the evidence does not support its use as an anxiety treatment in the absence of ADHD.
Key Evidence from Guidelines and Drug Labels
FDA Label Position (Highest Priority Evidence)
The FDA label explicitly addresses this question through controlled trials 1:
- In ADHD patients with comorbid anxiety: Two postmarketing trials demonstrated that atomoxetine "does not worsen" anxiety in patients already diagnosed with ADHD
- Pediatric trial (ages 8-17): 176 patients with ADHD plus separation anxiety disorder, generalized anxiety disorder, or social phobia showed atomoxetine did not worsen anxiety on the Pediatric Anxiety Rating Scale (PARS)
- Adult trial (ages 18-65): 442 patients with ADHD and social anxiety disorder showed atomoxetine did not worsen anxiety on the Liebowitz Social Anxiety Scale (LSAS)
Critical distinction: These trials assessed whether atomoxetine worsens existing anxiety in ADHD patients—not whether it treats anxiety as a primary disorder.
Clinical Practice Guidelines Explicitly Exclude Atomoxetine
The 2020 AACAP guideline for anxiety disorders in children and adolescents specifically states: "at present, the effectiveness of atomoxetine for the treatment of anxiety as the primary disorder has not been established, and as such atomoxetine is not further addressed in this guideline" 2.
The Japanese guidelines for social anxiety disorder (2023) recommend SSRIs and SNRIs (specifically venlafaxine) for anxiety treatment, with no mention of atomoxetine 3.
Research Evidence Shows Mixed Results
When Atomoxetine Showed Some Benefit:
- ADHD with comorbid anxiety: A 2022 systematic review found atomoxetine reduced anxiety symptoms in children/adolescents with ADHD, but this was in the context of treating ADHD first 4
- ADHD with social anxiety in adults: One RCT (2009) showed atomoxetine improved both ADHD and social anxiety symptoms, but only in patients with both diagnoses 5
- Comparative study: Atomoxetine showed faster anxiety reduction (by week 4) compared to methylphenidate in ADHD patients 6
When Atomoxetine Failed:
- Primary social anxiety disorder without ADHD: A 2009 controlled trial found no significant difference between atomoxetine and placebo for generalized social anxiety disorder in patients without ADHD (response rates: atomoxetine 21% vs placebo 33%) 7
Clinical Algorithm for Decision-Making
If the patient has:
Anxiety disorder WITHOUT ADHD → Do NOT use atomoxetine
ADHD WITH comorbid anxiety → Atomoxetine is a reasonable option
ADHD as primary concern with mild anxiety symptoms → Treat ADHD first
Important Caveats
Safety Monitoring Required
The FDA mandates close monitoring for:
- Suicidal ideation (black box warning in children/adolescents) 8, 9
- Clinical worsening and unusual behavioral changes, especially in first months or with dose changes 8
- Cardiovascular parameters (pulse, blood pressure) 9
Postmarketing Reports
There have been postmarketing reports of anxiety as an adverse effect of atomoxetine 1, highlighting that individual responses vary and some patients may experience worsening anxiety.
Time to Effect
Atomoxetine requires 6-12 weeks to reach full therapeutic effect for ADHD 8, making it unsuitable for acute anxiety management.
Bottom Line
Atomoxetine is an ADHD medication that happens not to worsen comorbid anxiety—it is not an anxiety treatment. The single controlled trial testing atomoxetine for primary anxiety disorder (without ADHD) showed no benefit over placebo 7. For anxiety as the primary diagnosis, use established treatments: SSRIs, SNRIs (venlafaxine/duloxetine), or CBT 3, 2.